Wall Street analysts forecast that West Pharmaceutical Services Inc. (NYSE:WST) will announce earnings per share of $0.72 for the current quarter, Zacks reports. Three analysts have made estimates for West Pharmaceutical Services’ earnings, with the highest EPS estimate coming in at $0.73 and the lowest estimate coming in at $0.70. West Pharmaceutical Services reported earnings of $0.73 per share in the same quarter last year, which indicates a negative year-over-year growth rate of 1.4%. The firm is scheduled to issue its next earnings results on Thursday, February 13th.
On average, analysts expect that West Pharmaceutical Services will report full-year earnings of $3.14 per share for the current financial year, with EPS estimates ranging from $3.13 to $3.15. For the next fiscal year, analysts forecast that the firm will report earnings of $3.45 per share, with EPS estimates ranging from $3.40 to $3.51. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover West Pharmaceutical Services.
West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, October 24th. The medical instruments supplier reported $0.79 EPS for the quarter, beating the Zacks’ consensus estimate of $0.71 by $0.08. West Pharmaceutical Services had a net margin of 12.82% and a return on equity of 16.66%. The business had revenue of $456.10 million for the quarter, compared to analyst estimates of $450.03 million. During the same quarter in the prior year, the business earned $0.76 EPS. West Pharmaceutical Services’s quarterly revenue was up 5.6% on a year-over-year basis.
Shares of NYSE:WST traded up $0.25 on Monday, reaching $150.40. 2,930 shares of the company’s stock were exchanged, compared to its average volume of 401,169. The company has a fifty day moving average of $142.94 and a 200-day moving average of $133.14. West Pharmaceutical Services has a twelve month low of $91.75 and a twelve month high of $152.10. The company has a market capitalization of $11.00 billion, a price-to-earnings ratio of 53.44, a PEG ratio of 3.38 and a beta of 1.25. The company has a current ratio of 3.00, a quick ratio of 2.31 and a debt-to-equity ratio of 0.17.
Several hedge funds and other institutional investors have recently bought and sold shares of WST. Northwestern Mutual Investment Management Company LLC raised its position in West Pharmaceutical Services by 0.3% in the 3rd quarter. Northwestern Mutual Investment Management Company LLC now owns 21,028 shares of the medical instruments supplier’s stock valued at $2,982,000 after purchasing an additional 70 shares in the last quarter. Coldstream Capital Management Inc. boosted its holdings in West Pharmaceutical Services by 4.0% in the second quarter. Coldstream Capital Management Inc. now owns 1,970 shares of the medical instruments supplier’s stock valued at $246,000 after purchasing an additional 76 shares during the last quarter. Kings Point Capital Management raised its stake in West Pharmaceutical Services by 3.2% during the second quarter. Kings Point Capital Management now owns 2,864 shares of the medical instruments supplier’s stock valued at $358,000 after buying an additional 90 shares in the last quarter. Stephens Inc. AR raised its stake in West Pharmaceutical Services by 3.0% during the second quarter. Stephens Inc. AR now owns 3,306 shares of the medical instruments supplier’s stock valued at $414,000 after buying an additional 96 shares in the last quarter. Finally, Cerebellum GP LLC raised its stake in West Pharmaceutical Services by 4.1% during the third quarter. Cerebellum GP LLC now owns 3,060 shares of the medical instruments supplier’s stock valued at $434,000 after buying an additional 121 shares in the last quarter. Institutional investors and hedge funds own 89.18% of the company’s stock.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
Featured Story: Growth Stocks, What They Are, What They Are Not
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.